-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 26, 2021, Merck and Ridgeback announced the latest clinical data for the oral COVID-19 drug Molnupiravir for the treatment of mild to moderate COVID-19
According to the data of all hospitalized patients, the hospitalization rate or mortality rate will be reduced by 30%
On October 1, 2021, Merck and Ridgeback announced the Phase III clinical interim data of Molnupiravir in the treatment of patients with mild to moderate COVID-19 pneumonia
The hospitalization or mortality rate in the Molnupiravir treatment group was 7.
Molnupiravir reduced hospitalization or mortality by 50%, with a p-value of 0.
In terms of mortality, there were no deaths in the treatment group and 8 deaths in the control group
In addition, the United Kingdom is the first country in the world to approve the listing of Molnupiravir
The Molnupiravir update has an effective rate of only 30% for all patients, which is much lower than the 50% in the interim analysis
Affected by this news, Merck's stock price fell 4% before its listing, its competitor Pfizer's stock price rose 6%, mRNA vaccine company Moderna's stock price rose 13%, and BioNtech's stock price rose 10%
Summarize
In the past two months, people's mood about the new crown pneumonia epidemic has repeatedly changed in hope and anxiety, and the stock prices of related pharmaceutical companies have also fluctuated
The success of Merck and Pfizer's oral medications for new coronary pneumonia has greatly increased confidence in defeating the epidemic
